Aligos Therapeutics, Inc..
ALGS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Aligos Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies to address liver diseases with high unmet medical need. The company's pipeline includes drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH). Aligos is developing mul...Show More
Better Health for All
20
Aligos Therapeutics is a biopharmaceutical company entirely focused on developing novel therapies for liver and viral diseases with high unmet medical needs, such as chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and COVID-19.
1
This core business model is inherently health-positive, with no evidence of harmful revenue streams. The company's R&D expenses were $14.0 million for Q2 2025
2
and $70.3 million for 2024,
3
representing 100% of its capital allocation towards health improvement. Its investigational drugs, ALG-000184 and ALG-055009, have shown favorable tolerability profiles in clinical trials, with adverse events similar to placebo for ALG-055009
4
and no viral breakthrough for ALG-000184.
5
The company's clinical trials are described as randomized, double-blind, and active-controlled multicenter studies,
6
indicating adherence to ethical standards. Aligos is also developing ALG-097558 as a potential treatment for COVID-19, with a study beginning in 2024,
7
demonstrating engagement in global health crisis response. However, the company's Code of Business Conduct and Ethics only generally requires compliance with laws and regulations,
8
and its press releases contain forward-looking statements and discuss inherent risks,
9
which suggests a moderate level of risk transparency rather than industry-leading practices. Furthermore, Aligos does not currently offer expanded access for its investigational products,
10
indicating an inflexible approach to patent use in relation to global health needs.
Fair Money & Economic Opportunity
0
Aligos Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for liver diseases, not a financial institution.
1
The provided articles detail its clinical trial progress, financial results, and corporate governance. There is no evidence that the company offers lending, deposit, or other financial services to consumers or businesses. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to Aligos Therapeutics, Inc.
Fair Pay & Worker Respect
20
All full-time employees are eligible to participate in the company's health and welfare plans, which include medical, dental, and vision benefits, as well as short-term and long-term disability insurance and life and AD&D insurance.
1
However, the benefit of the company paying the employee portion of premiums for health and welfare benefits is not available to all salaried employees.
2
Fair Trade & Ethical Sourcing
0
No information regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend was found in the provided articles for Aligos Therapeutics, Inc.
1
Honest & Fair Business
-40
Aligos Therapeutics has a whistleblower policy, detailed in its Code of Business Conduct and Ethics, which includes a 24/7 ethics hotline (email and phone) allowing for anonymous reporting.
1
The company prohibits retaliation against employees or directors who report concerns in good faith and protects confidentiality.
2
The Audit Committee Charter, adopted October 8, 2020, mandates the committee to establish procedures for the receipt, retention, and treatment of complaints regarding accounting, internal accounting controls, or auditing matters, and for the confidential and anonymous submission of concerns by employees.
3
However, there is no explicit evidence of independent investigation processes for these reports. The Audit Committee must consist of at least three directors, and each member must satisfy the independence requirements of Nasdaq and the SEC.
4
The company's Code of Business Conduct and Ethics defines a 'significant financial interest' as ownership greater than 5% of a material customer, supplier, or competitor, or an investment representing more than 5% of an employee's total assets.
5
A 'material' customer or supplier is defined as one with payments exceeding $120,000 in the past year.
6
The Code of Business Conduct and Ethics serves as the company's 'code of ethics' under the Sarbanes-Oxley Act of 2002.
7
Kind to Animals
0
No specific, concrete data points were found in the provided articles regarding Aligos Therapeutics, Inc.'s animal welfare practices, policies, or performance across any of the defined KPIs. The articles discuss general industry practices, advocacy efforts by third-party organizations,
1
and financial or collaboration details,
2
,
3
,
4
,
5
but do not provide direct evidence attributable to ALGS.US concerning animal testing, cruelty-free certifications, humane operations, wildlife conservation, ethical sourcing, or related initiatives.
6
,
7
,
8
,
9
No War, No Weapons
0
The provided articles for Aligos Therapeutics, Inc. focus on corporate governance, business conduct, and drug development for liver and viral diseases. None of the articles contain any information, quantitative data, or specific details related to arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other metrics relevant to the 'No War, No Weapons' ethical value. Therefore, no KPIs can be scored based on the evidence provided.
Planet-Friendly Business
-10
In 2023, the company's carbon footprint was 672 metric tons CO2 equivalent.
1
Its electricity consumption in 2023 was 1,247,000 kWh, with 37.6% sourced from renewables (23.9% solar and 13.7% wind).
2
The company has a carbon offset reduction target of 25% by 2026.
3
Respect for Cultures & Communities
0
No evidence available to assess Aligos Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
10
Aligos Therapeutics, Inc. provides users with data control options, including rights to access, portability, rectification, erasure, restriction of processing, objection, and withdrawal of consent, consistent with GDPR requirements.
1
The company demonstrates good regulatory compliance by identifying itself as a GDPR Data Controller, appointing an EU GDPR Representative, and providing a Data Protection Officer email.
2
For data transfers outside the EEA and UK, the company relies on the European Commission's standard contractual clauses.
3
The company states it collects basic contact, applicant, device, mobile network, and standard web information, and retains information only as long as reasonably necessary for specified purposes, indicating good data minimization practices.
4
Zero Waste & Sustainable Products
0
No specific, concrete data points or initiatives related to waste management, product recyclability, sustainable packaging, or other zero waste and sustainable product metrics were found in the provided articles for ALGS.US.
1
The articles primarily contained financial information or general statements about ESG transparency without specific details on waste-related KPIs.